Skip to main content
Intermediate Technical IVT

disease-modifying antirheumatic drug

Medication that can slow or halt the progression of rheumatic diseases by suppressing inflammation.

Full Definition

Disease-modifying antirheumatic drugs (DMARDs) are a class of medications designed to suppress the underlying inflammatory and immune processes that drive rheumatic diseases, potentially preventing joint damage and disease progression. In pediatric rheumatology, DMARDs are subdivided into conventional synthetic DMARDs (such as methotrexate, sulfasalazine, and leflunomide) and biologic DMARDs (including TNF inhibitors, IL-1 inhibitors, and others). Unlike symptomatic treatments such as NSAIDs, DMARDs address the root pathophysiology of inflammatory arthritis and are considered first-line therapy for conditions like juvenile idiopathic arthritis. The choice of DMARD depends on disease subtype, severity, and patient-specific factors.

Usage

Usage note: Often abbreviated as DMARD; distinguish between conventional synthetic and biologic types.

In Context

  • "The patient was started on a disease-modifying antirheumatic drug to prevent joint damage progression." — Treatment plan documentation
  • "Regular monitoring is required when children are receiving disease-modifying antirheumatic drugs." — Safety protocol

Also known as

DMARD antirheumatic therapy

Don't confuse with

NSAID corticosteroid analgesic

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON